Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Given Average Recommendation of "Buy" by Brokerages

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Get Free Report) has been given a consensus recommendation of "Buy" by the nine brokerages that are currently covering the firm, MarketBeat Ratings reports. Eight research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. The average twelve-month price objective among brokers that have covered the stock in the last year is $63.57.

Several analysts recently commented on CRBP shares. Piper Sandler began coverage on Corbus Pharmaceuticals in a report on Monday, December 2nd. They issued an "overweight" rating and a $35.00 price objective for the company. HC Wainwright restated a "buy" rating and set a $75.00 price target on shares of Corbus Pharmaceuticals in a research note on Tuesday, February 18th. StockNews.com upgraded shares of Corbus Pharmaceuticals to a "sell" rating in a research note on Thursday. Finally, William Blair assumed coverage on shares of Corbus Pharmaceuticals in a research report on Friday, February 28th. They set an "outperform" rating for the company.

Corbus Pharmaceuticals Trading Down 2.6 %

CRBP stock traded down $0.18 on Tuesday, hitting $6.79. The company had a trading volume of 168,155 shares, compared to its average volume of 247,677. The stock has a market cap of $82.70 million, a price-to-earnings ratio of -1.45 and a beta of 2.63. The stock's 50-day simple moving average is $10.09 and its 200 day simple moving average is $21.18. Corbus Pharmaceuticals has a 12-month low of $6.54 and a 12-month high of $61.90.

Remove Ads

Institutional Investors Weigh In On Corbus Pharmaceuticals

Institutional investors have recently bought and sold shares of the business. Charles Schwab Investment Management Inc. lifted its position in shares of Corbus Pharmaceuticals by 224.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 93,643 shares of the biopharmaceutical company's stock valued at $1,932,000 after acquiring an additional 64,800 shares in the last quarter. State Street Corp boosted its position in shares of Corbus Pharmaceuticals by 34.6% during the 3rd quarter. State Street Corp now owns 595,576 shares of the biopharmaceutical company's stock valued at $12,287,000 after acquiring an additional 153,243 shares during the last quarter. JPMorgan Chase & Co. grew its holdings in shares of Corbus Pharmaceuticals by 27.0% in the third quarter. JPMorgan Chase & Co. now owns 5,507 shares of the biopharmaceutical company's stock valued at $114,000 after purchasing an additional 1,172 shares in the last quarter. Geode Capital Management LLC increased its position in Corbus Pharmaceuticals by 8.1% in the third quarter. Geode Capital Management LLC now owns 249,759 shares of the biopharmaceutical company's stock worth $5,154,000 after purchasing an additional 18,702 shares during the last quarter. Finally, HighVista Strategies LLC increased its position in Corbus Pharmaceuticals by 94.1% in the third quarter. HighVista Strategies LLC now owns 75,292 shares of the biopharmaceutical company's stock worth $1,553,000 after purchasing an additional 36,499 shares during the last quarter. Hedge funds and other institutional investors own 64.64% of the company's stock.

Corbus Pharmaceuticals Company Profile

Corbus Pharmaceuticals Holdings, Inc, a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity.